An uncontrolled trial in early stage NSCLC patients suggested that bexarotene may modulate expression of biomarkers such as cyclins D1 and 3, and epidermal growth factor receptor (EGFR) [33], [50], [51], [52]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.